JP2023516381A - Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物 - Google Patents
Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物 Download PDFInfo
- Publication number
- JP2023516381A JP2023516381A JP2022552782A JP2022552782A JP2023516381A JP 2023516381 A JP2023516381 A JP 2023516381A JP 2022552782 A JP2022552782 A JP 2022552782A JP 2022552782 A JP2022552782 A JP 2022552782A JP 2023516381 A JP2023516381 A JP 2023516381A
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- fluorophenyl
- oxy
- carboxamide
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200026381 | 2020-03-03 | ||
| KR10-2020-0026381 | 2020-03-03 | ||
| PCT/KR2021/002622 WO2021177721A1 (ko) | 2020-03-03 | 2021-03-03 | Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516381A true JP2023516381A (ja) | 2023-04-19 |
| JP2023516381A5 JP2023516381A5 (cg-RX-API-DMAC10.html) | 2024-03-12 |
Family
ID=77612768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552782A Pending JP2023516381A (ja) | 2020-03-03 | 2021-03-03 | Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230099204A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4115887A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023516381A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210111711A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115209900A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021177721A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP4011885A4 (en) * | 2019-08-02 | 2023-01-18 | Wellmarker Bio Co., Ltd. | CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| KR20230144483A (ko) * | 2022-04-06 | 2023-10-16 | 웰마커바이오 주식회사 | Ron 돌연변이와 관련된 두경부암 예방 또는 치료용 약학 조성물 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019182274A1 (en) * | 2018-03-08 | 2019-09-26 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
| JP2022543250A (ja) * | 2019-08-02 | 2022-10-11 | ウェルマーカー・バイオ・カンパニー・リミテッド | オキソ-ピリジン縮合環誘導体、およびそれを含む医薬組成物 |
| JP2022554042A (ja) * | 2019-09-06 | 2022-12-28 | ウェルマーカー・バイオ・カンパニー・リミテッド | バイオマーカー型治療用組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101390076B1 (ko) | 2006-11-08 | 2014-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 피리디논 화합물 |
| CN102816175B (zh) * | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 |
| US20160206608A1 (en) | 2011-08-02 | 2016-07-21 | Pfizer Inc. | Crizotinib for use in the treatment of cancer |
| WO2013155223A1 (en) * | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| KR101350006B1 (ko) * | 2012-09-06 | 2014-02-13 | 씨제이제일제당 (주) | 피리돈 유도체를 포함하는 단백질 키나제 억제제 |
| ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| WO2016018087A1 (ko) * | 2014-07-29 | 2016-02-04 | 재단법인 아산사회복지재단 | Egfr-표적제제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도 |
| CN107406492B (zh) * | 2014-09-03 | 2021-12-24 | 井标记生物 | 用于预测对蛋白激酶抑制剂的敏感性的生物标记物及其用途 |
| JP2023513675A (ja) * | 2020-02-06 | 2023-04-03 | ウェルマーカー・バイオ・カンパニー・リミテッド | Kras変異に関連する癌の予防または治療のための医薬組成物 |
-
2021
- 2021-03-03 US US17/800,141 patent/US20230099204A1/en not_active Abandoned
- 2021-03-03 WO PCT/KR2021/002622 patent/WO2021177721A1/ko not_active Ceased
- 2021-03-03 EP EP21764686.8A patent/EP4115887A4/en not_active Withdrawn
- 2021-03-03 CN CN202180017888.8A patent/CN115209900A/zh active Pending
- 2021-03-03 JP JP2022552782A patent/JP2023516381A/ja active Pending
- 2021-03-03 KR KR1020210028396A patent/KR20210111711A/ko active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019182274A1 (en) * | 2018-03-08 | 2019-09-26 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
| JP2022543250A (ja) * | 2019-08-02 | 2022-10-11 | ウェルマーカー・バイオ・カンパニー・リミテッド | オキソ-ピリジン縮合環誘導体、およびそれを含む医薬組成物 |
| JP2022554042A (ja) * | 2019-09-06 | 2022-12-28 | ウェルマーカー・バイオ・カンパニー・リミテッド | バイオマーカー型治療用組成物 |
Non-Patent Citations (3)
| Title |
|---|
| "Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance", ONCOTARGET, vol. 10, no. 13, JPN6025003442, 2019, pages 1320 - 1333, ISSN: 0005732661 * |
| "KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis", PNAS, vol. 116, no. 44, JPN6025003441, 2019, pages 22122 - 22131, ISSN: 0005732662 * |
| MICHELE L. BABICKY ET AL., ONCOGENE, vol. 38, JPN6025020442, 2019, pages 5599 - 5611, ISSN: 0005732663 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021177721A1 (ko) | 2021-09-10 |
| EP4115887A1 (en) | 2023-01-11 |
| US20230099204A1 (en) | 2023-03-30 |
| EP4115887A4 (en) | 2024-07-17 |
| CN115209900A (zh) | 2022-10-18 |
| KR20210111711A (ko) | 2021-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4115887A1 (en) | Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present | |
| US20230346790A1 (en) | Pharmaceutical composition for prevention or treatment of cancers associated with kras mutation | |
| TW202529768A (zh) | 癌症治療的療法 | |
| CA3110901C (en) | Combination therapy for treating blood cancer | |
| JP6147246B2 (ja) | Akt及びmek阻害剤化合物の組み合わせ、及び使用方法 | |
| MX2014009303A (es) | Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer. | |
| WO2021018032A1 (en) | Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease | |
| JP2008514726A (ja) | ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法 | |
| JP6526789B2 (ja) | 組み合わせ療法 | |
| EP1885187B1 (en) | Methods for treating drug resistant cancer | |
| US20230241073A1 (en) | Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with ron mutantation, and method using same | |
| US20230242521A1 (en) | Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same | |
| US20230076733A1 (en) | Combination Therapy | |
| Robert et al. | 5 BRAF and MEK Inhibitors | |
| HK1110477B (en) | Methods for treating drug resistant cancer | |
| HK1232877A1 (en) | Association between 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione and an egfr tyr kinase inhibitor | |
| NZ617243B2 (en) | Combinations of akt and mek inhibitor compounds, and methods of use | |
| HK1193754A (en) | Combinations of akt and mek inhibitor compounds, and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240301 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240301 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250527 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251118 |